{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T10:17:21Z","timestamp":1778667441692,"version":"3.51.4"},"reference-count":32,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2021,3,20]],"date-time":"2021-03-20T00:00:00Z","timestamp":1616198400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background: First-line treatment for patients with non-small cell lung cancer (NSCLC) with a sensitizing epidermal growth factor receptor (EGFR) mutation is a tyrosine kinase inhibitor (TKI). Despite higher response rates and prolonged progression free survival (PFS) compared with platinum doublet chemotherapy, a subset of these patients do not receive prolonged benefit from these agents. We investigate if the neutrophil-to-lymphocyte ratio (NLR) and other markers of cachexia and chronic inflammation correlate with worse outcomes in these patients. Methods: This study is a retrospective review of 137 patients with advanced EGFR-mutated NSCLC treated with TKIs at Rush University Medical Center and University of Chicago Medicine from August 2011 to July 2019, with outcomes followed through July 2020. The predictive value of NLR and body mass index (BMI) was assessed at the start of therapy, and after 6 and 12 weeks of treatment by univariable and multivariable analyses. Results: On univariable analysis, NLR \u2265 5 or higher NLR on a continuous scale were both associated with significantly worse PFS and overall survival (OS) at treatment initiation, and after 6 or 12 weeks of treatment. On multivariable analysis, NLR \u2265 5 was associated with increased risk of death at 12 weeks of therapy (HR 3.002, 95% CI 1.282\u20137.029, p = 0.011), as was higher NLR on a continuous scale (HR 1.231, 95% CI 1.063\u20131.425, p = 0.0054). There was no difference in PFS and OS and amongst BMI categories though number of disease sites and Eastern Cooperative Oncology Group (ECOG) performance status was associated with worse PFS and OS. Conclusions: Patients with NLR \u2265 5 have a worse median PFS and median OS than patients with NLR &lt; 5. NLR may have value as a predictive biomarker and may be useful for selecting patients for therapy intensification in the front-line setting either at diagnosis or after 12 weeks on therapy. NLR needs to be validated prospectively.<\/jats:p>","DOI":"10.3390\/cancers13061426","type":"journal-article","created":{"date-parts":[[2021,3,21]],"date-time":"2021-03-21T22:00:37Z","timestamp":1616364037000},"page":"1426","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Neutrophil-to-Lymphocyte Ratio Is a Predictive Biomarker in Patients with Epidermal Growth Factor Receptor (EGFR) Mutated Advanced Non-Small Cell Lung Cancer (NSCLC) Treated with Tyrosine Kinase Inhibitor (TKI) Therapy"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3668-9618","authenticated-orcid":false,"given":"Nicole K.","family":"Yun","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Rush University Medical Center, Chicago, IL 60612, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sherin J.","family":"Rouhani","sequence":"additional","affiliation":[{"name":"Section of Hematology\/Oncology, Department of Medicine, The University of Chicago Comprehensive Cancer Center, Chicago, IL 60637, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine M.","family":"Bestvina","sequence":"additional","affiliation":[{"name":"Section of Hematology\/Oncology, Department of Medicine, The University of Chicago Comprehensive Cancer Center, Chicago, IL 60637, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ethan M.","family":"Ritz","sequence":"additional","affiliation":[{"name":"Bioinformatics and Biostatistics Core, Rush University Medical Center, Chicago, IL 60612, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brendan A.","family":"Gilmore","sequence":"additional","affiliation":[{"name":"Hematology, Oncology and Cell Therapy, Department of Medicine, Rush University Medical Center, Chicago, IL 60612, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Imad","family":"Tarhoni","sequence":"additional","affiliation":[{"name":"Cell &amp; Molecular Medicine, Pathology, Rush University Medical Center, Chicago, IL 60612, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey A.","family":"Borgia","sequence":"additional","affiliation":[{"name":"Cell &amp; Molecular Medicine, Pathology, Rush University Medical Center, Chicago, IL 60612, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Batus","sequence":"additional","affiliation":[{"name":"Hematology, Oncology and Cell Therapy, Department of Medicine, Rush University Medical Center, Chicago, IL 60612, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip D.","family":"Bonomi","sequence":"additional","affiliation":[{"name":"Hematology, Oncology and Cell Therapy, Department of Medicine, Rush University Medical Center, Chicago, IL 60612, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary Jo","family":"Fidler","sequence":"additional","affiliation":[{"name":"Hematology, Oncology and Cell Therapy, Department of Medicine, Rush University Medical Center, Chicago, IL 60612, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,3,20]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21590","article-title":"Cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1159\/000492344","article-title":"Neutrophil to Lymphocyte Ratio as a Prognostic Factor in European Patients with Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer Treated with Tyrosine Kinase Inhibitors","volume":"41","author":"Santiago","year":"2018","journal-title":"Oncol. Res. Treat."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1913662","article-title":"Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC","volume":"382","author":"Ramalingam","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Fang, W., Huang, Y., Hong, S., Zhang, Z., Wang, M., Gan, J., Wang, W., Guo, H., Wang, K., and Zhang, L. (2019). EGFR exon 20 insertion mutations and response to osimertinib in non-small-cell lung cancer. BMC Cancer, 19.","DOI":"10.1186\/s12885-019-5820-0"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Derman, B.A., Macklis, J.N., Azeem, M.S., Sayidine, S., Basu, S., Batus, M., Esmail, F., Borgia, J.A., Bonomi, P., and Fidler, M.J. (2017). Relationships between longitudinal neutrophil to lymphocyte ratios, body weight changes, and overall survival in patients with non-small cell lung cancer. BMC Cancer, 17.","DOI":"10.1186\/s12885-017-3122-y"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Forget, P., Khalifa, C., Defour, J.P., Latinne, D., Van Pel, M.C., and De Kock, M. (2017). What is the normal value of the neutrophil-to-lymphocyte ratio?. BMC Res Notes, 10.","DOI":"10.1186\/s13104-016-2335-5"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1038\/bjc.2012.292","article-title":"A derived neutrophil to lymphocyte ratio predicts survival in patients with cancer","volume":"107","author":"Proctor","year":"2012","journal-title":"Br. J. Cancer"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e11648","DOI":"10.1097\/MD.0000000000011648","article-title":"The peripheral blood neutrophil-to-lymphocyte ratio is a prognostic predictor for survival of EGFR-mutant nonsmall cell lung cancer patients treated with EGFR-TKIs","volume":"97","author":"Zhang","year":"2018","journal-title":"Medicine"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"214","DOI":"10.21037\/tlcr.2019.06.10","article-title":"Prognostic role of pretreatment neutrophil-to-lymphocyte ratio in non-small cell lung cancer patients treated with systemic therapy: A meta-analysis","volume":"8","author":"Wang","year":"2019","journal-title":"Transl. Lung Cancer Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"180","DOI":"10.14740\/wjon1069w","article-title":"Neutrophil-to-Lymphocyte Ratio Predicts Overall Survival of Advanced Non-Small Cell Lung Cancer Harboring Mutant Epidermal Growth Factor Receptor","volume":"8","author":"Minami","year":"2017","journal-title":"World J. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"423","DOI":"10.2147\/IJGM.S174605","article-title":"The prognostic impact of neutrophil to lymphocyte ratio in advanced non-small cell lung cancer patients treated with EGFR TKI","volume":"11","author":"Phan","year":"2018","journal-title":"Int. J. Gen. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.ejso.2018.09.026","article-title":"Sarcopenia is an independent unfavorable prognostic factor of non-small cell lung cancer after surgical resection: A comprehensive systematic review and meta-analysis","volume":"45","author":"Deng","year":"2019","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Ono, T., Igawa, S., Kurahayashi, S., Okuma, Y., Sugimoto, A., Kusuhara, S., Ozawa, T., Fukui, T., Sasaki, J., and Mitsufuji, H. (2020). Impact of neutrophil-to-lymphocyte ratio in patients with EGFR-mutant NSCLC treated with tyrosine kinase inhibitors. Investig. New Drugs.","DOI":"10.1007\/s10637-020-00919-0"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"443","DOI":"10.5301\/tj.5000632","article-title":"Significance of neutrophil-to-lymphocyte ratio in Western advanced EGFR-mutated non-small cell lung cancer receiving a targeted therapy","volume":"103","author":"Meriggi","year":"2017","journal-title":"Tumori J."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"886","DOI":"10.21037\/tlcr.2019.11.16","article-title":"Prognostic biomarkers in stage IV non-small cell lung cancer (NSCLC): Neutrophil to lymphocyte ratio (NLR), lymphocyte to monocyte ratio (LMR), platelet to lymphocyte ratio (PLR) and advanced lung cancer inflammation index (ALI)","volume":"8","author":"Mandaliya","year":"2019","journal-title":"Transl. Lung Cancer Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/S0002-9440(10)62529-1","article-title":"Tumor-derived granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor prolong the survival of neutrophils infiltrating bronchoalveolar subtype pulmonary adenocarcinoma","volume":"159","author":"Wislez","year":"2001","journal-title":"Am. J. Pathol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"295","DOI":"10.3389\/fonc.2019.00295","article-title":"A Novel Paradigm Between Leukocytosis, G-CSF Secretion, Neutrophil-to-Lymphocyte Ratio, Myeloid-Derived Suppressor Cells, and Prognosis in Non-small Cell Lung Cancer","volume":"9","author":"Tavakkoli","year":"2019","journal-title":"Front Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.coi.2018.03.009","article-title":"Plasticity of myeloid-derived suppressor cells in cancer","volume":"51","author":"Tcyganov","year":"2018","journal-title":"Curr. Opin. Immunol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/imr.12459","article-title":"Neutrophils in the tumor microenvironment: Trying to heal the wound that cannot heal","volume":"273","author":"Singel","year":"2016","journal-title":"Immunol. Rev."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s13045-019-0836-0","article-title":"Increased neutrophil extracellular traps promote metastasis potential of hepatocellular carcinoma via provoking tumorous inflammatory response","volume":"13","author":"Yang","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/j.amjsurg.2017.08.003","article-title":"Cancer-promoting mechanisms of tumor-associated neutrophils","volume":"214","author":"Hurt","year":"2017","journal-title":"Am. J. Surg."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Jaillon, S., Ponzetta, A., Di Mitri, D., Santoni, A., Bonecchi, R., and Mantovani, A. (2020). Neutrophil diversity and plasticity in tumour progression and therapy [published online ahead of print, 2020 Jul 21]. Nat. Rev. Cancer.","DOI":"10.1038\/s41568-020-0281-y"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"102820","DOI":"10.1016\/j.critrevonc.2019.102820","article-title":"Combination of EGFR-TKIs and chemotherapy in advanced EGFR mutated NSCLC: Review of the literature and future perspectives","volume":"146","author":"Rebuzzi","year":"2020","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1001\/jamaoncol.2020.1260","article-title":"Effect of Osimertinib and Bevacizumab on Progression-Free Survival for Patients With Metastatic EGFR-Mutant Lung Cancers: A Phase 1\/2 Single-Group Open-Label Trial","volume":"6","author":"Yu","year":"2020","journal-title":"JAMA Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Nakagawa, K., Garon, E.B., Seto, T., Nishio, M., Ponce Aix, S., Paz-Ares, L., Chiu, C.H., Park, K., Novello, S., and Nadal, E. (2019). Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol., 1655\u20131669.","DOI":"10.1016\/S1470-2045(19)30634-5"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Marcoux, N., Gettinger, S.N., O\u2019Kane, G., Arbour, K.C., Neal, J.W., Husain, H., Evans, T.L., Brahmer, J.R., Muzikansky, A., and Bonomi, P.D. (2019). EGFR-Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes. J. Clin. Oncol., 278\u2013285.","DOI":"10.1200\/JCO.18.01585"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"9020","DOI":"10.1200\/JCO.2019.37.15_suppl.9020","article-title":"Early clearance of plasma EGFR mutations as a predictor of response to Osimertinib and comparator EGFR-TKIs in the FLAURA trial","volume":"37","author":"Zhou","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Cheng, H., Hosgood, H.D., Deng, L., Ye, K., Su, C., Sharma, J., Yang, Y., Halmos, B., and Perez-Soler, R. (2020). Survival Disparities in Black Patients With EGFR-mutated Non-small-cell Lung Cancer. Clin. Lung Cancer, 177\u2013185.","DOI":"10.1016\/j.cllc.2019.07.003"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Leduc, N., Atallah, V., Agossou, M., Vinh-Hung, V., Orre, M., Sargos, P., and Molinie, V. (2017). Lung Adenocarcinoma Survival in EGFR-Mutated African-Caribbean Patients: A Multicenter Study in the French West Indies. Target Oncol., 689\u2013693.","DOI":"10.1007\/s11523-017-0512-7"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Jones, C.C., Mercaldo, S.F., Blume, J.D., Wenzlaff, A.S., Schwartz, A.G., Chen, H., Deppen, S.A., Bush, W.S., Crawford, D.C., and Chanock, S.J. (2018). Racial Disparities in Lung Cancer Survival: The Contribution of Stage, Treatment, and Ancestry. J. Thorac. Oncol., 1464\u20131473.","DOI":"10.1016\/j.jtho.2018.05.032"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1200\/JCO.2017.74.2049","article-title":"Racial and Ethnic Disparities in Cancer Survival: The Contribution of Tumor, Sociodemographic, Institutional, and Neighborhood Characteristics","volume":"36","author":"Ellis","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"6688346","DOI":"10.1155\/2021\/6688346","article-title":"Neutrophil-Lymphocyte Ratio as a Prognostic Parameter in NSCLC Patients Receiving EGFR-TKIs: A Systematic Review and Meta-Analysis","volume":"2021","author":"Tang","year":"2021","journal-title":"J. Oncol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/6\/1426\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T05:38:36Z","timestamp":1760161116000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/6\/1426"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,20]]},"references-count":32,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2021,3]]}},"alternative-id":["cancers13061426"],"URL":"https:\/\/doi.org\/10.3390\/cancers13061426","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,20]]}}}